Emulating interactions between microorganisms and tumor microenvironment to develop cancer theranostics

Tongmeng Jiang1, Tao Yang1, Yingfan Chen1, Yao Miao1, Yajing Xu1, Honglin Jiang1, Mingying Yang2, Chuanbin Mao1,3

1. School of Materials Science and Engineering, Zhejiang University, Hangzhou, Zhejiang 310027, P. R. China
2. Institute of Applied Bioresource Research, College of Animal Science, Zhejiang University, Yuhangtang Road 866, Hangzhou, Zhejiang 310058, P. R. China
3. Department of Chemistry and Biochemistry, University of Oklahoma, Norman, OK 73019, USA

Corresponding authors: Mingying Yang (E-mail: yangm@zju.edu.cn) and Chuanbin Mao (E-mail: maophage@gmail.com or cbmao@ou.edu).

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Received: 2022.01.04; Accepted: 2022.03.01; Published: 2022.03.14

Abstract

The occurrence of microorganisms has been confirmed in the tumor microenvironment (TME) of many different organs. Microorganisms (e.g., phage, virus, bacteria, fungi, and protozoa) present in TME modulate TME to inhibit or promote tumor growth in species-dependent manners due to the special physiological and pathological features of each microorganism. Such microorganism-TME interactions have recently been emulated to turn microorganisms into powerful cancer theranostic agents. To facilitate scientists to explore microorganisms-TME interactions further to develop improved cancer theranostics, here we critically review the characteristics of different microorganisms that can be found in TME, their interactions with TME, and their current applications in cancer diagnosis and therapy. Clinical trials of using microorganisms for cancer theranostics are also summarized and discussed. Moreover, the emerging technology of whole-metagenome sequencing that can be employed to precisely determine microbiota spectra is described. Such technology enables scientists to gain an in-depth understanding of the species and distributions of microorganisms in TME. Therefore, scientists now have new tools to identify microorganisms (either naturally present in or introduced into TME) that can be used as effective probes, monitors, vaccines, or drugs for potentially advancing cancer theranostics to clinical applications.

Key words: microorganisms, tumor microenvironment (TME), cancer theranostics, microbiota spectra

1. Introduction

Cancer has been reported as one of the leading causes of death and a monster that tortures the quality of life worldwide in the 21st century [1]. Urgency has been coming out since its diagnosis and therapy remain challenging. For centuries, the knowledge of tumor microenvironment (TME) stands for the interaction of cancer cells and the milieu networks around them, providing insights for understanding how the heterogeneous cells generate, proliferate, migrate, develop and even invade or contaminate normal cells in nature [2]. Recently, numerous studies have demonstrated that microorganisms play pivotal roles in forming and changing TME and developing cancer theranostics [3].

Microorganisms include all kinds of microbiota such as bacteria, viruses, phages, protozoa, and fungi [4]. Great evidence has been presented to highlight the impacts of microorganisms in physiological and pathological features, such as metabolism, inflammation, and immunity [5]. Traditional ideas mainly focus on the dysbiosis of microorganisms and their nosogenetic impacts of inducing a variety of diseases, including but not restricted to rheumatoid arthritis [6], HIV [7], Parkinson’s disease [8], liver cirrhosis [9],
inflammatory bowel disease [10], graft-versus-host disease [11], type 2 diabetes mellitus [12] and different kinds of cancer [13]. However, the advantages of microorganisms have been ignited up by recent findings and current strategies. Symbiotic microorganisms live commensally in bodies and modulate health and development from prenatal to postnatal periods through microbiota-host interactions [14]. There are trillions of commensal microorganisms naturally existing in skin [15], lung [16], oral cavity [17], esophageal [18], stomach [19], gut [20], vagina [21] and etc. Battle with pathogenic microorganisms maintains homeostasis and regulates overall health. Moreover, a new epoch has been in advent due to the development of incumbent technologies based on in vivo imaging [22], CRISPR/Cas 9 [23], phage display [24] and immunotherapy [25], leading to more convenient and effective prognostics, diagnosis and therapies for various diseases, especially cancer.

Over the past several decades, a new approach, theranostics, referring to diagnostics and therapy, sparked the prosperity of cancer treatment with high accuracy and specificity owing to the development of nanomedicine [26]. Conventional theranostic platforms using inorganic nanoparticles such as iron oxide nanoparticles (IONP), gold-based nanoparticles and quantum dots (QD) present great potential advantages and seem to reach the clinical translation status [26]. However, they leave some drawbacks such as low biocompatibility, high toxicity, non-biodegradability and lack of targeting [26]. Hence, biological obstacles, including enzymatic substrates, naturally-derived transporters, microorganisms, and cells, were applied to overcome the former blemishes and further improved the next generation of cancer theranostics [26]. Among these biological obstacles, microorganisms are known for their easy applications in the area of cancer theranostics by serving as probes [27], monitors [28], drugs [29] or immunotherapeutic composites [30]. More importantly, the microorganisms per se provide unique structures and characteristics that make themselves beneficial for cancer theranostics. For example, the head of T4 phage contains immunomodulators [31] that can be exploited for cancer therapy [32]. Oncolytic vesicular stomatitis virus (VSV) stimulates the innate immune system and proinflammatory responses, thus inhibiting melanoma [33]. Also, as an immunomodulator, Listeria monocytogenes may induce bacteria for stimulating CD8+ cytotoxic T-cells that are cancer killers [34]. Ganoderma sinense inhibits H1299 non-small-cell lung cancer ex vivo and in vivo [35] mainly because it contains polysaccharides that can regulate immune cells and induce cytokines [25]. Application of Trypanosoma cruzi epimastigotes aggrandizes the NADPH oxidase activity to inhibit tumorigenesis because it systematically activates macrophages, dendritic cells, CD4+ and CD8+ T cells [36]. Therefore, microorganisms are promising next-generation theranostic platforms.

However, there are still challenges for using microorganisms in the field of cancer theranostics because of the complicated interactions between cancer cells and microorganisms. First, the distinctive structures and properties of different microorganisms exert distinguished contributions to different cancers. Second, even the same microorganisms affect cancer cell proliferation, progression, and death discrepantly at different stages or time points of the tumor development for the same type of cancer. Third, cancer cells excrete growth factors and molecules, thereby influencing the survival and functions of the microorganisms. Moreover, in normal TME, oncogenic microbiota induce oncogenesis, beneficial microbiota suppresses oncogenesis, and engineered microbiota injected into normal TME could serve as tumor monitors or diagnostic factors. In contrast, engineered microbiota injected into TME could not only provide monitor functions but also act as therapeutic factors, developing TME into an oncolytic milieu (Figure 1). This review explores the basic knowledge of the characteristics of microorganisms, their interaction with cancer, and their potential applications for cancer theranostics.

Figure 1. Microorganisms existing in normal tumor microenvironment (TME) and oncolytic TME present different functions. Oncogenic microorganism expressed molecules that stimulate oncogenesis. Engineered microorganisms are designed as monitors or diagnostic factors in normal TME, and serve as monitors or therapeutic factors in oncolytic TME. Some microorganisms are acting as anti-tumoral therapeutics themselves in TME.
2. Structures and properties of microorganisms used in cancer theranostics

2.1. Bacterial viruses (phages)

In general, bacterial viruses, which are referred to as bacteriophages or phages, are verified to bear capacities in infecting bacteria. They cannot replicate without host cells in nature [37]. Phages are generally viruses containing single or double-stranded nucleic acids (DNA or RNA) that are protected by proteins with or without tails. They are principally classified into two categories, including lytic phages and lysogenic phages, depending on the replication status when they are formed in the host cells [38]. Basically, phages range from 24 to 400 nm in size [39], and consist of the capsid (head), which protects the genetic materials with or without tails and other exceptions [40, 41]. Lytic phages are named by their lytic cycle, whereas lysogenic phages only follow the lysogenic cycle [42]. Genetic materials of the phages are integrated into and replicated along with the host cells at the lysogenic cycle [43], followed by the lytic cycle if activated [43]. Lytic phages used the host biosynthetic machines to produce the genetic materials, coated with proteins and lysis proteins before mature phages appear. Then the mature phages get the host cells ruptured since enough lysis proteins accumulated [42, 44]. Filamentous phages such as M13, fd, and f1 are lysogenic and replicate without killing the host cells. They are thus usually used in phage display technology to express peptides or antibodies, especially on pIII and pVIII proteins [45]. Unlike filamentous phages, T7 phage presents proteins or peptides on the capsid protein gp10B [46]. In addition, the highly immunogenic outer capsid protein (gene product hoc) in phages can modulate the immune response; especially, the gene product hoc in T4 phage head contains immunoglobulin superfamilies [31]. Therefore, they are candidates for cancer therapy [32] (Figure 2A).

2.2. Oncolytic viruses

Viruses other than bacterial viruses, especially oncolytic viruses, are the ones that could exist in tumors for cancer theranostics. Oncolytic viruses are tumor-selective replicating tools, which can effectively kill tumor cells with acceptable side effects on normal cells [47]. Several viruses have exhibited their oncolytic characteristics, such as adenovirus, vesicular stomatitis virus (VSV), vaccinia virus, reovirus, and herpes simplex virus (HSV) because of their unique structures [47]. For example, an adenovirus contains episomal dsDNA ranging from 30kb to 38kb and is coated with a capsid mostly carrying RDG motifs. It could infect a large number of cells with integrins or coxsackievirus and adenovirus receptor (CAR) no matter whether they are dividing or not [47]. Likewise, the G protein on the VSV surfaces infects many tumorous cells [48], the H protein on the spike of measles virus recognizes CD46 or signaling lymphocyte activation molecule (SLAM) on mammal cells [49], and the envelope glycoproteins (gB&gC) on HSV interact with the surface heparin sulfated proteoglycans (HSPGs) on mammal cells to further help glycoproteins (gD) stimulate nectin-1 or herpes viral entry mediators (HVEM) on mammal cells [50]. Thus, they provide enough biological access for genetic editing and gene modification. Especially, they can be armed with luciferase genes, fluorescent proteins or radio-labelled substrate molecules for tumor imaging [51] as well as siRNA, shRNA or therapeutics for tumor inhibiting [52]. For example, engineered Newcastle disease virus with apolipoprotein could activate tumor death [53] (Figure 2B). Oncolytic viruses are also activators of toll-like receptor signaling pathways, which induce the acute inflammatory reactions of local tumors [33].

2.3. Bacteria

Bacteria are single-cell microorganisms basically consisting of cell walls, cell membranes, cytoplasm, nuclear bodies, and other spatial structures, including capsule, flagellum, fimbria, and endospore. Bacteria were used as an anti-cancer agent by German physicians one hundred and fifty years ago. Since then, they have been found useful in cancer therapy. Tumors regressed when they were infected by certain kinds of bacteria, such as Streptococcus pyogenes for neck cancer, Bacillus Calmette–Guérin (BCG) for bladder cancer, and Clostridium histolyticum for metastatic cancer [54, 55]. Some bacteria are naturally existing to form colonization and inherent to tumors, and thus they can excrete anti-cancerous enzymes or agents by mesosomes and ribosomes. More specifically, anaerobic bacteria can easily survive in the TME with underprivileged oxygen, but anaerobic bacteria could destroy the tumor. Gram-negative anaerobes, such as Salmonella could get into the tumors and grow both inside and outside, while Gram-positive anaerobes, such as Clostridia and Bifidobacteria, proliferate in the TME without or with oxygen even in the presence of tumor necrosis [54]. Owing to the simple genomes of bacteria, they could be genetically engineered as vectors to carry and deliver various anti-cancerous agents, including but not limited to siRNA, shRNA, microRNA, therapeutic DNA, immunomodulators, antiangiogenic and cytotoxic molecules [56]. Bacteria that could uptake nanoparticles or imaging agents (i.e. 18F-FDS) as food
granules could be employed in tumor monitoring and imaging [57]. The flagella and LPS in the cell wall are mediators for different immune cells, including CD8+ T cells, Treg cells, macrophage, NK cell and dendritic cells in TME [58] (Figure 2C).

### 2.4. Fungi

Fungi are eukaryotic organisms, which can attack, infect or influence the human body under diverse circumstances. Cell walls are critical components of fungi (including mushroom and yeast), which help assist fungi in resisting environmental stress and invading ecological niches [59]. Polysaccharides make up more than 90% of fungi cell walls with extension decorations determined by the pathogens [60], which are currently called “pathogen-associated molecular patterns” (PAMPs), including β-glucan, mannans, and chitin [61] (Figure 2D). Human bodies recognize PAMPs by innate immune cells through cascade signaling pathways of pro-inflammatory and anti-inflammatory cytokines, such as retinoic acid-inducible gene 1 (RIG-I)-like receptors (RLRs), nucleotide oligomerization domain (NOD)-like receptors (NLRs), Toll-like receptors (TLRs) and C-type lectin receptors (CLRs) [62]. Pro-inflammatory cytokines are often key factors inducing oncogenesis [63], whereas anti-inflammatory cytokines may support cancer therapy [64].

### 2.5. Protozoa

Protozoa are eukaryotic organisms dwelling in extracellular fluids or inside host cells due to their innate evasion and resistance to the human immune system [65]. There are several strategies for protozoa to get away from humoral immune defenses so that they could further affect human bodies. Firstly, an isomeric host complement-mediated compound named 160-kD glycoprotein (gp160) is expressed to conjugate C3b and C4b and then suppress the complement-mediated lysis of protozoa [66, 67]. Some protozoa such as Leishmania have modified surface lipophosphoglycan (LPG), which acts as a barrier to protect parasites from being attacked by lytic C5b-C9 membrane attack complex (MAC) [68]. Similarly, other protozoa like Trypanosoma brucei resist primate-specific trypanosome lysis factors (TLFs) based cytotoxicity due to their well-known structure called flagellar pocket [69]. Trypanosoma cruzi may present similar effects on the mammalian cells due to its same flagellum structure [70]. Plasmodium falciparum expressed VAR2CSA that could target tumors for cancer theranostics [71]. Secondly, protozoa remodel the compartments of host cells and inhibit host cell signaling pathways that contribute to antimicrobial mechanisms [65]. Toxoplasma gondii restricts the fusion of lysosomes and endosomes by dwelling in phagosomes, whereas T. cruzi destroys the Ca2+-regulated lysosomal exocytic pathway in mammalian cells [72]. Thirdly, some protozoa (i.e., Plasmodium falciparum) impair the capacity of dendritic cells (DCs) to activate antigen-specific primary
and secondary T cell responses by binding to myeloid DCs [73]. *Plasmodium falciparum* exerts some organelles (i.e., rhoptry, microneme and dense granule) just like *Toxoplasma gondii*, therefore, both may display some similar properties in the TME. Sporozoites of *Theileria annulate* and *Theileria parva* transformed into schizonts in mammalian leucocytes, meanwhile stimulating apoptotic and proinflammatory effects [74] (Figure 2E).

3. Interactions between microorganisms and tumors

Normally, microorganisms influence the homeostasis of the host. Some microbial communities reside in the oral, skin, gut, nasal cavity, lung, pancreas, prostate, urinary or genital tract and coexist with the human body peacefully. In contrast, others stimulate chronic immune reactions or even enter tumors. For one thing, pathogenic microorganisms contribute to disease development by excreting metabolites, stimulating an immune response, and activating inflammatory pathways. For another, commensal microorganisms residing at the barrier sites exert protecting effects through resisting pathogens and regulating the immune response and metabolism of the host, such as inducing migration of immune cells, stimulating chemokines and cytokines etc [13]. In the TME, the relationship between microorganisms and tumors depends on the place of tumor occurrence as well as the category of microorganisms. For decades, some TMEs, in particular in the lung, have long been demonstrated as a sterile environment by oncologists. However, this hypothesis has been challenged by the current technologies and recent studies [75]. There is increasing evidence that microorganisms are naturally present in tumors or around tumors, constitute TME, and participate in tumor development. In addition, some microorganisms restrict the development of tumors on the one hand, and some others contribute to tumor growth on the other hand.

3.1. Microorganisms naturally present in tumors of different organs

3.1.1. Respiratory tract

Many microbiotas reside in the upper and lower respiratory tract from the nasal cavity, pharynx, larynx to the trachea, bronchi, and lung. Among them, several microorganisms are living with respiratory tumors. Significant different diversities of bacterial microbiomes have been detected using bacterial 16S rRNA sequencing between the normal nasal cavity and malignant nasal neoplasia [76]. Gong et al. compared the profiles of microbiotas among normal larynx, laryngeal cancer, and the normal tissues adjacent to laryngeal cancer and found the different populations of microorganisms among them [77]. Evidence has also shown the discrepancies of microorganisms in other lung cancer tissues by biopsy or bronchoscopy [78].

3.1.2. Oral-gut axis

The digestive tract begins from the oral cavity to the anus throughout from the outside of the body to the inside of the body as well as the appendicle organs, including the liver, gallbladder, and pancreas. Thus a majority of microorganisms live in the digestive tract. Since it is a long tract of tubes with complexities of structures and circumstances, there are multiple factors to generate divers of tumors by microbiome residents, including pathogenic, opportunistic, and commensal microorganisms. Different from the infective and opportunistic microbiota in the digestive tract leading to cancer, the commensal microbiomes could promote the body’s health and prevent cancer [79]. To date, the data of commensal microbiomes in the digestive tract has been well established, especially in the gut.

3.1.3. Urinary-genital axis

Similar to the gastrointestinal tract, the genitourinary organs are also easy to form tumors and have abundant commensal microorganisms because the sterile environment of the genitourinary tract has been abandoned [80]. In an interesting way, the *Actinomyces* and BCG around and in bladder cancer prevent tumor relapses and show potential treatment effects for bladder cancer [81]. For females, HPV-induced cervical carcinogenesis has been demonstrated to be linked with microbiota dysbiosis in the vagina/cervix and cervical cancer [82]. Not coming singly but in pairs, for males, Bacteroides and Streptococcus species have been detected in prostate cancer. However, their roles need further exploration [83].

3.2. Microorganisms naturally present in TME

Once upon a time, the infection of microbiomes, including phages, viruses, bacteria, fungi, protozoa etc. has been concerned because it is thought to result in tumorigenesis and carcinogenesis not only in situ but also in distant tissues or organs. Pathogenic microorganisms play multiple oncogenic roles that contribute to cancer formation and development. A wide range of microorganisms can get through the human body from skin, mouth, and other trenches like wounds. There are a large number of studies reporting the relationship of pathogenic viruses and tumors, such as Epstein-Barr virus (EBV) for
nasopharyngeal carcinoma [84], hepatitis virus for liver cancer [85], human papillomavirus (HPV) for oropharyngeal [86] and cervical cancer [87], and human T-lymphotropic virus for leukemia [88]. Likewise, bacteria are also the sinful archcriminal in oncogenesis. For example, *Helicobacter pylori* (*H. pylori*) contributes to gastric cancer [89], *Bacteroidetes, Verrucomicrobia*, and *Proteobacteria* to gut cancer [90], and *Veillonella, Megasphaera* to lung cancer [91]. What is more, fungi and protozoa are also criminals that promote the initiation and development of cancer. For example, *Aspergillus flavus* lead to liver cancer [92], and *Liver fluke Clonorchis sinensis* causes cholangiocarcinoma [93]. Besides, microorganisms naturally present in TME sometimes play an anti-tumor role. This phenomenon was mostly found in phages and bacteria. In this section, we discussed the oncogenic roles (phages, viruses, bacteria, fungi, and protozoa) and the anti-tumorous roles (phages and bacteria) of microorganisms naturally in TME (Table 1-3).

### 3.2.1. Bacterial viruses (phages)

As microorganisms naturally present in the environment, phages are also present in the human body and TME [94]. Firstly, phages are suspected to bind integrin proteins (e.g. αIIbβ3, αvβ3), which are expressed on tumorous cells and activated T cells [95]. Secondly, phages can mediate invading pathogens that are tumor inducers [96], and thus may suppress tumor growth. In particular, endogenous phages modulate bacteria in the oral-gut axis, therefore maintaining the microbiota homeostasis in TME [96]. Third, phages can stimulate different immune cells, which are important cells in TME. For example, T4 phages activate dendritic cells [97], inhibit CD3 receptor-induced T-cell proliferation, and stimulate the migration of granulocytes and mononuclear cells [98]. In addition, phages control the homeostasis of host immune reactions in tumor-bearing animals and humans, therefore influencing TME [99]. Some metagenomic analysis presents certain type of phages related to TME [96, 100], and those residing in TME [96] are listed in Table 1.

### 3.2.2. Other viruses

Viruses naturally present in TME are oncogenic factors. Some viruses express oncogenes which induce tumorigenesis by influencing cell cycles and DNA damage processes [101]. For instance, E6 and E7 expressed by HPV induce anal cancer, cervical cancer, and vaginal cancer; LANA and v-cyclin expressed by Kaposi’s sarcoma herpes virus (KSHV) induce Kaposi’s sarcoma and primary effusion lymphoma; NS3, NS4B, NS5A and core proteins expressed by hepatitis C virus (HCV) induce hepatocellular carcinoma; HBsAg and HBx expressed by hepatitis B virus (HBV) induce hepatocellular carcinoma; EBNA-1, EBNA-2 LMP-1, and LMP-2 expressed by Epstein-Barr virus (EBV) induce Burkitt’s lymphoma, nasopharyngeal cancer, Hodgkin and non-Hodgkin’s lymphoma, etc [102]. We summarized these viruses in Table 2. In particular, the therapeutic approaches for those oncogenic are also included in this table. Moreover, the above oncogenes can also target tumors by binding molecules on the tumorous cells [102]. Besides, viruses stimulate oncogenic inflammation by mediating STAT3, MAPK, and NFκB and signaling pathways [103]. Also, viruses induce cancers by causing tissue injury. For example, HBV and HCV trigger liver cirrhosis and hepatocarcinogenesis [104]. Additionally, some viruses promote tumor growth and progression by modulating cytokine/chemokine networks [105] and manipulating cell cycles and DNA damage processes [101].

### Table 1. Phages in TME and their potential functions

| Phage                    | Tumor                          | Function in TME | Ref |
|--------------------------|--------------------------------|-----------------|-----|
| Acinetobacter phage Acj61 | Colorectal cancer              | Unknown         | [96]|
| Aeromonas phage FX29     | Colorectal cancer              | Unknown         | [96]|
| Bacillus phage PFEFR-5   | Colorectal cancer              | Host-Bacillus cereus | [96]|
| Clostridium phage phiCT9441A | Colorectal cancer            | Unknown         | [96]|
| Enterobacteria phage HK629 | Liver metastasis of colorectal cancer | Unknown         | [96]|
| Enterobacteria phage HK697 | Liver metastasis of colorectal cancer | Unknown         | [96]|
| Enterobacteria phage M13  | Liver metastasis of colorectal cancer | Unknown         | [96]|
| Enterobacteria phage mEp460 | Liver metastasis of colorectal cancer | Unknown         | [96]|
| Enterobacteria phage P1   | Liver metastasis of colorectal cancer | Unknown         | [96]|
| Enterobacteria phage P2   | Liver metastasis of colorectal cancer | Host-Enterobacteriaca | [96]|
| Enterobacteria phage P88  | Liver metastasis of colorectal cancer | Unknown         | [96]|
| Enterobacteria phage VT2p_272 | Liver metastasis of colorectal cancer | Unknown         | [96]|
| Enterobacteria phage λ    | Liver metastasis of colorectal cancer | Host-Enterobacteriaca | [96]|
| Enterobacteria phage φ80  | Liver metastasis of colorectal cancer | Unknown         | [96]|
| Escherichia phage PEECO 4 | Liver metastasis of colorectal cancer | Unknown         | [96]|
| Escherichia phage pro483  | Liver metastasis of colorectal cancer | Unknown         | [96]|
| Escherichia phage TL-2011b | Liver metastasis of colorectal cancer | Unknown         | [96]|
| Lactobacillus phage Lb338-1 | Colorectal cancer            | Unknown         | [96]|

https://www.thno.org
Table 2. Other viruses in TME and their potential functions and therapeutics

| Other Viruses                                      | Tumor                                         | Function                           | Therapeutic approach                        | Ref   |
|----------------------------------------------------|-----------------------------------------------|------------------------------------|---------------------------------------------|-------|
| Acanthamoeba polyphaga mouvirus                    | Colorectal cancer                             | Unknown                            |                                             | [96]  |
| AcMNPV                                             | Colorectal cancer and liver metastasis        | Unknown                            |                                             | [96]  |
| Cafeteria roenbergensis virus                      | Colorectal cancer and liver metastasis        | Unknown                            |                                             | [96]  |
| CMV                                                | Colorectal cancer                             | Unknown                            |                                             | [96]  |
| EBV                                                | Burkitt’s lymphoma, nasopharyngeal cancer,    | Oncogenic                          | Vaccine; Acyclovir                          | [102] |
| ETVV                                               | Colorectal cancer and liver metastasis        | Unknown                            | Vaccine; Interferon; Antiviral agents       | [102] |
| HBV                                                | Hepatocellular carcinoma                      | Oncogenic                          | Vaccine; Interferon; Antiviral agents       | [102] |
| HCV                                                | Hepatocellular carcinoma                      | Oncogenic                          | Vaccine; Antiviral agents                   | [102] |
| HCV genotype 1                                     | Liver metastasis of colorectal cancer         | Unknown                            |                                             | [96]  |
| HIV-1                                              | Colorectal cancer and liver metastasis        | Unknown                            |                                             | [96]  |
| HIV-11                                             | Colorectal cancer and liver metastasis        | Unknown                            |                                             | [96]  |
| HIV-2                                              | Colorectal cancer and liver metastasis        | Unknown                            |                                             | [96]  |
| HIV-7                                              | Colorectal cancer and liver metastasis        | Unknown                            |                                             | [96]  |
| HPV                                                | Cervical cancer, vaginal                      | Oncogenic                          | Vaccine                                     | [102] |
| HTLV-1                                             | Adult T cell lymphoma                         | Oncogenic                          | No effective vaccine                        | [102] |
| KSHV                                               | Kaposi’s sarcoma, primary effusion lymphoma   | Oncogenic                          | Antiviral agents                            | [102] |
| Lymphocystis disease virus                         | Colorectal cancer                             | Unknown                            |                                             | [96]  |
| Megavirus viurnis                                  | Colorectal cancer                             | Unknown                            |                                             | [96]  |
| MCV                                                | Merkel cell carcinoma                         | Oncogenic                          | Unknown                                     | [102] |
| Pandoravirus dulcis                                | Colorectal cancer and liver metastasis        | Unknown                            |                                             | [96]  |
| Pandoravirus neocaledonia                          | Colorectal cancer and liver metastasis        | Unknown                            |                                             | [96]  |
| Pandoravirus salinus                               | Colorectal cancer and liver metastasis        | Unknown                            |                                             | [96]  |
| Qinghai Himalayan marmot astrovirus                | Colorectal cancer and liver metastasis        | Unknown                            |                                             | [96]  |
| Simian virus 40                                    | Colorectal cancer                             | Unknown                            |                                             | [96]  |
| Tipula oleracea nudivirus                          | Colorectal cancer and liver metastasis        | Unknown                            |                                             | [96]  |
| Torque teno midi virus 5                           | Liver metastasis of colorectal cancer         | Unknown                            |                                             | [96]  |
| Torque teno midi virus 9                           | Liver metastasis of colorectal cancer         | Unknown                            |                                             | [96]  |
| Torque teno virus 16                               | Colorectal cancer                             | Unknown                            |                                             | [96]  |
| Torque teno virus 24                               | Colorectal cancer                             | Unknown                            |                                             | [96]  |

Table 3. Bacteria/Fungi/Protozoa in TME and their potential functions and therapeutics

| Bacteria/Fungi/Protozoa | Tumor                                         | Function                           | Therapeutic approach | Ref   |
|-------------------------|-----------------------------------------------|------------------------------------|-----------------------|-------|
| *Anaerococcus mediterraneensis* | Colorectal cancer | Unknown                            | Antibiotics           | [107] |
| *Bacillus cereus*        | Colorectal cancer                             | Unknown                            | Antibiotics           | [107] |
| *Bacteroides fragilis*   | Colorectal cancer                             | Unknown                            | Antibiotics           | [107] |
| *Enterococcus faecalis*  | Colorectal cancer                             | Unknown                            | Antibiotics           | [107] |
| *Escherichia coli*       | Colorectal cancer and liver metastasis        | Unknown                            | Antibiotics           | [107] |
| *Fusobacterium nucleatum*| Colorectal cancer                             | Unknown                            | Antibiotics           | [107] |
| *Klebsiella pneumoniae*  | Colorectal cancer and liver metastasis        | Unknown                            | Antibiotics           | [107] |
| *Porphyromonas gingivalis*| Colorectal cancer                             | Unknown                            | Antibiotics           | [107] |
| *Prevotella denticola*   | Colorectal cancer                             | Unknown                            | Antibiotics           | [107] |
| *Streptococcus anginosus*| Colorectal cancer                             | Unknown                            | Antibiotics           | [107] |
| *Streptococcus pneumoniae*| Colorectal cancer                             | Unknown                            | Antibiotics           | [107] |
| *Ascomycota*             | Pancreatic ductal adenocarcinoma               | Unknown                            | Oncogenic             | [111] |
| *Basidiomycota*          | Pancreatic ductal adenocarcinoma               | Unknown                            | Oncogenic             | [111] |
| *Candida albicans*       | Renal cell carcinoma; squamous cell carcinoma | Oncogenic                          | Anti-Toxoplasma drugs | [112] |
| *Malassezia globosa*     | Pancreatic ductal adenocarcinoma               | Oncogenic                          | Anti-Toxoplasma drugs | [112] |
| *Toxoplasma gondii*      | Brain, lung, prostate, cervix, and endometrial cancers | Oncogenic                          | Anti-Toxoplasma drugs | [112] |
3.2.3. Bacteria

Similar to viruses, bacteria are also modulators of inflammation and induce oncosgenesis [106]. For example, FadA molecules expressed by *Fusobacterium nucleatum* regulate the inflammation and oncosgenesis in colorectal cancer due to its binding to E-cadherin and activation of β-catenin signalling [107]. In addition, *F. nucleatum* also plays tumorigenic roles in inhibiting T cell proliferation and inducing T cell apoptosis in colorectal cancer [108]. Bacteria also produce carcinogens such as bile acids, H₂S and deoxycholic acid [109]. In contrast to the oncogenic effects of bacteria, they also exert important anti-cancer effects by modulating the cytokine/chemokine networks and immune cells in TME [34], especially for some commensal bacteria in colon cancer [110] (Table 3).

3.2.4. Fungi

The roles of fungi naturally existing in TME are also oncogenic. They produce carcinogens such as nitrosamines and acetaldehyde [109]. Glycans as major components of fungal walls trigger complement cascade in TME [111]. Another mechanism for fungi to promote cancer is molecular mimicry [109]. For instance, *Candida albicans* expresses complement receptor 3-related protein (CR3-RP), which has a similar structure to CR3 on the leukocytes, interfering with the immune response in TME [109] (Table 3).

3.2.5. Protozoa

Traditionally, protozoa are parasites not only known as pathogenic factors but also play tumorigenic roles. The oncogenic roles of protozoa are mainly manifested in stimulating inflammation, modulating cytokine/chemokine networks, and triggering the response of immune cells [112]. For instance, the interleukin-12 triggered by *Toxoplasma gondii* stimulates T cells and natural killer (NK) cells in promoting cancer [112] (Table 3). Recently, studies show that the functions of microorganisms introduced into TME play anti-tumorous roles, which we are discussed in the next section.

4. Applications of microorganisms used in cancer theranostics

In terms of theranostics, the potential applications of microorganisms for cancer have been well established with the development of nanotechnology. Over the past decades, phage display and other microbiome-based carriers have played a major role in cancer theranostics not only by catering molecules or drugs directly to tumors but also by allowing the visualization or detection of cancer. In this part, we review different microbiota used for cancer diagnosis and therapy (Table 4-8).

---

### Table 4. Phages applied for cancer structure and therapy.

| Phages                   | Technology/Mechanism          | Diagnosis/Monitor                      | Therapy                                                                 |
|-------------------------|-------------------------------|----------------------------------------|-------------------------------------------------------------------------|
| M13 (e.g. M13mp19 [116, 119], M13KO7 [30, 117, 124, 192], etc.; T4 [32], T7 [46]; fd phage [122], fd-tet [123]) | Page display | Screen Oligopeptides [116], antigen binding fragment [117] and gene-specific affibody [192] for cancer targeting imaging and diagnosis | Screen peptides for targeted therapy of cancer [119]; Generating gene-targeting agents for cancer therapy [30]; Generating monoclonal antibody for cancer chemotherapy [124]; Generating vaccines; [32, 46] Guiding the delivery of small interfering RNA (siRNA) for cancer gene therapy [123]; Acting as immunomodulators [193] in vivo |

### Table 5. Oncolytic viruses applied for cancer diagnosis and therapy.

| Oncolytic virus | Technology/Mechanism          | Diagnosis/Monitor                      |
|-----------------|-------------------------------|----------------------------------------|
| Adenovirus [133-135], HSV-1 [136], Measles virus [137]: Newcastle disease virus [53]; Parvovirus [138]: Vaccinia virus [139]; VSV [140-142] | Adding luciferase genes, fluorescent proteins or radio-labelled substrates into virus | Bioluminescence imaging, fluorescence imaging and nuclear medicine-based imaging [51] |
| Adenovirus [132]; HSV-1 [136]; Measles virus [137]; Newcastle disease virus [53]; Poliovirus [138]; Vaccinia virus [143]; VSV [140-142]; Reovirus [194] | Anti-proliferation, anti-apoptosis and immune modulators; Vectors for gene therapy | Acting as an oncolytic agent [50, 145]; Applied for cancer immunotherapy [144]; Delivery of molecules, siRNA and shRNA for cancer gene therapy [52, 146] |

### Table 6. Bacteria applied for cancer diagnosis and therapy.

| Bacteria                  | Technology/Mechanism          | Diagnosis/Therapy                        |
|---------------------------|-------------------------------|------------------------------------------|
| Escherichia coli [57]     | 9F-FDS uptake by bacteria strain | Nuclear medicine-based imaging           |
| Escherichia coli [149]    | Stimulating apoptotic and autophagic effects by products | Anti-tumor effects on cell lines in vitro |
| Listeria monocytogenes [34, 152] | Modulating immune cells and cytokine/chemokine networks | Acting as an oncolytic agent; Applied for cancer immunotherapy in vivo |
| Salmonella Typhimurium [150] | Vectors for gene therapy | Delivery of tumor antigen, DNA plasmids, siRNA and shRNA for cancer gene therapy in vivo |
4.1. Bacterial viruses (phages)

The boost of phage display opens a new era for cancer theranostics, especially since this technology was awarded Nobel Prize in 2018 [113]. Phage display can be used to visualize cancer location and further reflect the behaviors and activities of cancer [114]. Phage display technology has contributed to cancer theranostics in the following aspects (Table 4). First, phage antibody library screening is used for selecting accurate targets for detecting cancer at the early stage. Second, phage display-derived peptides are utilized as imaging probes for monitoring cancer. Third, phages containing nanoparticles or small molecules as drugs could help prognosticate cancer. For instance, a phage-displayed random peptide library can be used to identify the epitope sequences, such as pinpointing CSPG4 as a target for theranostics of B-cell lymphoma [115]. Likewise, integration of an M13mp19 phage-displayed peptide library and a microfluidic system discovered cancer cell-specific oligopeptides for ovarian cancer diagnosis (Figure 3) [116]. AF680-labeled phage nanoparticles with targeting peptides are utilized for ovarian cancer cell line imaging by fluorescent microscopy [22]. M13KO7 phage display was employed to isolate an anti-HER3 antigen-binding fragment as a near-infrared fluorescence imaging probe for imaging HER3-positive cancer through positron emission tomography (PET) (Figure 4) [117]. In addition, M13 phage based probe is a powerful method for the detection of circulating tumor cells [118]. Besides, peptides screened by M13mp19 phage display can also be applied for targeted cancer therapy by targeting the TME, receptors on cancerous cells, or tumor vasculature (Figure 5) [119].

Except for M13 phage, T4 and T7 phage display has also been employed for identifying tumorous antigens, screening targeting peptides, and generating vaccines for cancer theranostics [32, 46]. For example, we generated a naked eye counting system to detect the cancer-biomarker miRNAs by fluorescent T7 phage [120]. Besides, fd phage is applied for cancer diagnosis and therapy. For instance, we increased the detection sensitivity of anti-p53 antibody, a cancer biomarker, by a combination of antigens and fd phage nanofibers [121]. Our group has also developed antiangiogenic targeted breast cancer therapy based on angiogenin-binding peptides displayed on the side wall of fd phage as well as the tumor-homing peptides displayed at the tip of the same phage [122]. Moreover, coat proteins derived from fd-tet phages could guide the delivery of small interfering RNA (siRNA), leading to efficient breast cancer gene therapy [123]. Many clinical trials of monoclonal antibodies based on phage display have been launched for cancer chemotherapy [124], such as Mapatumumab for lymphoma [125], colorectal cancer [126], and Drozitumab for chondrosarcoma, ovarian and colorectal cancers [127].

4.2. Oncolytic viruses

Unlike phages, oncolytic viruses are utilized for cancer theranostics in a different way (Table 5). Oncolytic viruses are used as anti-cancer vaccines generally in two directions. First, large viruses can cause diseases and rarely replicate in normal tissues. But they are abundant in tumors such as poliovirus [128], herpes simplex virus (HSV) [50], adenovirus [52], and vaccinia virus [129]. These viruses bear virulence genes that replicate with tumor proliferation and play roles in anti-proliferation,
anti-apoptosis, and immune modulators (Figure 6) [51]. Second, small viruses have fast replication cycles and normally do not result in diseases, including vesicular stomatitis virus (VSV)[130] and reovirus [131]. These viruses are commonly used as vectors for gene therapy. Compared to large viruses, they are safer carriers for both in vitro and in vivo cell transfection [132]. Besides, many monitoring systems, including bioluminescence imaging, fluorescence imaging, and nuclear medicine-based imaging, are widely applied both experimentally and clinically, which is based on the backbones of oncolytic viruses (Adenovirus [133-135], HSV-1 [136], measles virus [137], Newcastle disease virus [53], parvovirus [138], vaccinia virus [139] and VSV [140-142]) or the genes armed on them [51]. For instance, engineered oncolytic measles virus (MV-GFP-HSNS-scEGFRvIII and MV-GFP-HAA-scEGFRvIII) can not only induce GFP expression for imaging the EGFRvIII-expressing glioma lines and xenografts but also present an antitumor activity [49]. Oncolytic adenoviruses not only can be armed with luciferase cDNA [133], green fluorescent protein (GFP) [134], and sodium/iodide symporter (NIS) (Figure 7) [135] for tumor imaging but also serve as vectors for the treatment of head-and-neck cancer [52]. In addition, engineered adenovirus evades innate immunity in vivo, decreases tumor growth, and prolongs survival of lung cancer-bearing mice (Figure 8) [143]. Nonpathogenic poliovirus triggers antitumor immune responses in TME, treating recurrent glioblastoma in clinical trials [144]. Vaccinia viruses not only trigger anti-tumoral immunity by immune cells but also act as vectors for gene therapy for cancers [145, 146].

Figure 3. Oligopeptides screened by phage display can be used for ovarian cancer diagnosis. Adapted with permission from [116], Copyright 2015, Ivyspring International Publisher; CC BY-NC 4.0.
Figure 4. Near-infrared fluorescence imaging probes based on M13KO7 phage display. Adapted with permission from [117], Copyright 2018, Ivyspring International Publisher, CC BY-NC 4.0.

Figure 5. Peptides screened by phage display and used for targeted cancer therapy. Adapted with permission from [119], Copyright 2019, Springer Nature Switzerland AG. Part of Springer Nature, CC BY 4.0.
Figure 6. Selection of oncolytic vaccinia virus for personalized therapy. Adapted with permission from [51]. Copyright 2012, Ivyspring International Publisher, CC BY-NC 4.0.

Figure 7. Oncolytic NIS-expressing adenovirus enhances cancer imaging in pancreatic cancer models. Adapted with permission from [135]. Copyright 2021, Elsevier, CC BY-NC-ND 4.0.
4.3. Bacteria

Traditionally, bacteria are thought to be deleterious organisms to the human body owing to their pathogenicity that causes different diseases such as infection and cancer [147]. Even though bacterial therapy for cancer was claimed as an effective approach a long time ago, it has not been actively studied until the recent findings show their multiple theranostic effects. Briefly, in cancer theranostics, bacteria have been employed as a probe to detect cancer, as a sensor to monitor cancer, and as a therapeutic drug to treat cancer (Table 6). Bacteria-derived elements can also be used as therapeutic drugs for cancer treatment. In addition, bacteria localized to TME modulate chemokines, cytokines, and tumor-infiltrating immune cells,
representing a new mechanism by which bacteria target and suppress cancer [148]. *Escherichia coli* strain MG1655 injected into tumor-bearing mice can uptake $^{18}$F-FDS to become visualized by PET imaging of tumors (Figure 9) [57]. Cytosine deaminase and 5-fluorocytosine derived from *Escherichia coli* inhibit mutant lung cancer A549 cells by activating apoptosis [149]. On the one hand, *Salmonella Typhimurium* VNP20009 itself injected into murine melanoma inhibits tumor growth and lung metastasis [150]. On the other hand, VNP20009 can also be used as a vector to deliver a specific gene to treat colon cancer in a mice model [151]. Likewise, *Listeria monocytogenes* and its products stimulate an immune response (inducing immune cells and modulating cytokines) and act as gene vectors for delivering therapeutics (tumor antigen, DNA plasmid, siRNA, shRNA, etc.) for cancer therapy (Figure 10) [34, 152]. These gene-targeted therapies are also widely found in *Clostridium* sp., *Escherichia coli*, and *Salmonella sp.* [153]. Mannose-sensitive hemagglutinin armed on *Pseudomonas aeruginosa* inhibits tumor growth and reverses epithelial-mesenchymal transition of skin cancer [154]. In addition, many *Listeria monocytogenes* and *Salmonella Typhimurium* strains are employed in cancer therapy [148].

### 4.4. Fungi

Similar to bacteria, fungi have also been found effective in cancer therapy (Table 7). Some compounds derived from medicinal fungi induce mitochondria-mediated apoptosis and thus kill cancer cells [155]. These studies investigated the anti-tumor effects of compounds derived from fungi *in vitro*. For instance, polysaccharide-K derived from a mushroom, *Coriolus versicolor*, stimulates apoptosis of leukemia HL-60 cells [156]. Ganodermic acids (B, Mf, Mk, S and T) and ribonuclease derived from another mushroom, *Ganoderma lucidum*, also trigger apoptosis in many human cancer cell lines, including colon cancer HCT116 cells [157]. Similarly, cordycepin derived from *Cordyceps militaris* (a mushroom) has been used as an anti-tumoral agent in leukemia U937 and NB-4 cells [158] because it can trigger apoptosis and autophagy. Compounds from *Laetiporus sulphureus* present cytotoxic effects on five cancer cell lines, including leukemia HL-60 cells, colorectal carcinoma SW-480 cells, breast cancer MCF-7 cells, lung cancer A-549 cells, and liver cancer SMMC-721 cells [159]. Polypeptides from *Pleurotus eryngii* suppress cervical, breast, and stomach cancer cells and modulate macrophages *in vitro* [160]. Extracts from *Inonotus obliquus* also inhibit prostatic adenocarcinoma PC-3 cells and breast carcinoma MDA-MB-231 cells [161]. Agglutinin from *Paecilomyces japonica* also exerts cytotoxic effects on human breast cancer MDA-MB-231 cells, human pancreas cancer AsPc-1 cells, and stomach cancer SNU-1 cells [162]. Pigments derived from Daldinia concentrica [163] and Xylaria schweinitzii [164] also present cytotoxicity against lung carcinoma SK-LU-I cells, hepatocellular carcinoma HepG2 cells, epidermal carcinoma KB cells, and breast carcinoma MCF7 cells. Lectins derived from *Hericium erinaceum* [165], *Russula delica* [166], *Russula lepida* [167], and laccase derived from *Tricholoma mongolicum* [168] can suppress the proliferation of HepG2 hepatoma cells and MCF7 breast cancer cells. Extracts from *Lepista inversa* also suppress cancer cell lines, including NCI-H460 (lung cancer), HCT-15 (colon cancer), AGS

**Figure 9.** Bacteria uptake $^{18}$F-FDS for tumor imaging by PET. Adapted with permission from [57]. Copyright 2020, Iivyspring International Publisher, CC BY 4.0.
(gastric cancer) and MCF-7 (breast cancer) [169]. Cytotoxic effects of 5-methylmellein from *Xylaria psidii* [170] and compounds (e.g. cytochalasin, pentaminolarin, xylochalasin, etc.) from *Xylaria sp.* [171] on colon cancer HCT116 cells, prostatic adenocarcinoma PC-3 cells, and MCF7 breast cancer cells are also found to result from the activation of apoptosis. Breast cancer cell lines are also inhibited by orf239342 from *Agaricus bisporus*, Brefeldin A from *Agaricus blazei*, ergosterol from *Amauroderma rude*, organic molecules from *Amauroderma rugosum* [172], culture broth and ethanolic extract from *Antrodia camphorate* [173], extracts from *Clitocybe alexandri* [169], extracts from *Coprinus comatus* [174], extracts from *Flammulina velutipes* [175], ethanol extracts from *Fomes fomentarius*, marmorin from *Hypsizigus marmoreus*, Panepoxydone from *Lentinus crinitus*, β-glucan from *Lentinus edodes*, extracts from *Lignosus rhinocerotis*, ribonuclease from *Lyophyllum shimeji*, chromatographic fractions from *Marasmius oreades*, hispolon from *Phellinus linteus*, antioxidant protein from *Pholiota nameko*, extracts from *Pleurotus ostreatus*, compounds from *Podostroma cornu-damae*, β-glucan from *Poria cocos*, polysaccharides from *Schizophyllum commune* [176]. Yet the immunomodulation effects of fungi develop a novel insight for oncologists to generate better therapeutic avenues for cancer treatments [177]. For example, a polysaccharide derived from a mushroom, *Boletus edulis*, increases the cytotoxic activity of the splenic natural killer cells and cytotoxic T lymphocytes, thus activating immune responses that inhibit the proliferation and growth of renal cancer in mice [177]. Likewise, oral administration of β-1,3-Glucan derived from yeast (*Saccharomyces cerevisiae*) in tumor-bearing mice stimulates granulocyte-macrophage progenitors and active cytokines such as IFN-γ, IL-1α, and IL-6, suppressing tumor progression [178].

Figure 10. Anticancer effects of *Listeria monocytogenes* through an immune response. Adapted with permission from [152], Copyright 2018, MDPI, Basel, Switzerland, CC BY 4.0.
In addition, fungal β-glucans accompanied with radiotherapy/chemotherapy have achieved positive therapeutic effects without obvious side effects on clinical trials of treating breast cancer, cervical cancer, gastrointestinal cancer, and prostate cancer [179]. Polysaccharides from *Ganoderma sinense* modulate the activities of immune cells and secretion of cytokines [25], therefore suppressing H1299 non-small-cell lung cancer *ex vivo* and *in vivo* (Figure 11) [35]. Similarly, D-Fraction from *Grifola frondosa* suppresses breast cancer both *in vivo* and *ex vivo*, as well as restricts lung metastases of breast cancer by modulating immune effects [180]. Mangrove-derived endophytic fungi inhibit *in vitro* angiogenesis of lung cancer induced by HPV-16 E7 oncoprotein [181]. Extracts from *Fomitopsis officinalis* not only exert apoptotic effects on cancer cells but also decrease tumor size and elongate the lifespan of tumor-bearing mice [182]. Nevertheless, more discoveries are needed to explore the potential of fungi in cancer diagnosis and therapy.

### 4.5. Protozoa

Due to the finding of the negative regulation impacts of protozoa on cancer progression [183], the anticancer action of protozoa and their products have been explored. Protozoa gradually gain their popular reputation not only in cancer treatment but also in cancer diagnosis and prognosis (Table 8). For example, VAR2CSA expressed by *Plasmodium falciparum* is a binding protein to oncofetal chondroitin sulfate, which is widely expressed in many types of tumors. Thus, *Plasmodium falciparum* expressing VAR2CSA and recombinant VAR2CSA (rVAR2) can be used as a targeting probe, together with therapeutic molecules for cancers theranostics (Figure 12) [71]. Leukocytes infected by *Theileria annulate* and *Theileria parva* potentially express cancer hallmarks including hypoxia inducible factor-1 alpha (HIF1α), transforming growth factor-beta (TGF-β), telomerase reverse transcriptase (TERT), murine double minute 2 (MDM2), nuclear factor-k-gene...
binding (NF-kB), T. annulata prolyl isomerase I gene (TaPIN1), matrix metalloproteinase-9 (MMP-9), tumor necrosis factor-alpha (TNF-α) and inhibitor of apoptosis protein (IAP), which are potential chemotherapeutic targets for cancer therapy [74]. Likewise, Toxoplasma gondii and Toxoplasma gondii-derived molecules stimulate or block multiple signaling pathways such as TNF-α, NF-kB activity in modulating tumor microenvironment [112]. Epimastigotes of Trypanosoma cruzi as vaccination could systematically activate macrophages, dendritic cells, CD4+ and CD8+ T cells, thereby increasing the NADPH oxidase activity to inhibit carcinogenesis (Figure 13) [36]. These actions thus potentially inhibit cancers.

5. Potential mechanisms of microorganisms in cancer theranostics

5.1 The roles of microorganisms in tumor cells

The roles of microorganisms in cancer theranostics can be divided into two major types: to regulate tumor cells and mediate immune cells. As shown in Figure 14 and Table 4-8, the microorganisms above, including phages, oncolytic viruses, bacteria, fungi, and protozoa, present direct roles on tumor cells. Phages not only display tumor-targeting molecules (i.e., peptides, fragments) [116, 117], but also serve as drug delivery systems for cargos such as siRNA and antibodies [123, 124]. Oncolytic viruses and bacteria play multi-functional roles in cancerous cells, including labeling them with imaging molecules (i.e., GFP, 18F-FDS and NIS) [51, 57], expressing cytotoxic components [50, 148], and delivering therapeutic agents [52, 153]. Fungi only present cytotoxicity because their structure contains multiple polysaccharides [176], but protozoa only interact directly with tumor cells by expressing tumor-targeting proteins [71]. In summary, the tumor-targeting effects of microorganisms are based on certain receptors on tumor cells [58, 71, 119], and the cytotoxic effects can be attributed to the stimulation of apoptotic (caspase 3/7, Bcl2, MAPK etc.) and autophagic pathways in tumor cells [53, 155, 184].

5.2 The roles of microorganisms in immune cells

The theranostic effects of microorganisms on cancer often rely on the cytokine networks or signaling pathways produced by immune cells in the host. Macrophages, dendritic cells, T cells, and NK cells are the most common types of immune cells triggered by microorganisms. Bacteria can stimulate

![Figure 12](https://www.thno.org)
the anti-tumoral effects through the use of macrophages to activate IL-1β/TNF-α signaling [148], and the use of fungi/fungi extract to activate IL-1α/IL-6/IFN-γ signaling [178]. Dendritic cells can also excrete IL-1β to further enhance CD8+ T cells and NK cells to produce IFN-γ when phages [97], bacteria [148], or protozoa [36, 185] are used to treat diseases. The downstream signaling pathways of NFκB, STAT, and TLR triggered by CD8+ T cells, Treg cells, and NK cells also participate in the microorganism-based cancer therapy [34, 145, 186].

Figure 13. Trypanosoma cruzi extracts elicit protective immune response against chemically induced colon and mammary cancers. Adapted with permission from [36]. Copyright 2015, UICC, John Wiley and Sons.
Figure 14. Potential functions of microorganisms on tumor cells for cancer theranostics. Phages and protozoa can display tumor-targeting agents such as peptides. Oncolytic viruses and bacteria can be labelled with imaging agents such as GFP, NIS and so on. Phages oncolytic viruses and bacteria are possible vectors for delivering certain therapeutics including apoptin, siRNA and antibodies. Oncolytic viruses, bacteria, fungi and protozoa contain or express cytotoxic components that can assist cancer therapy.

6. Clinical trials of microorganisms in cancer theranostics

In addition, many clinical trials have been launched, ongoing, or completed in the field of microorganisms applied for cancer theranostics. We searched these trials registered in ClinicalTrials.gov (https://clinicaltrials.gov/) and EudraCT (https://www.clinicaltrialsregister.eu) and only listed all the completed studies that used microorganisms or engineered microorganisms directly in Table 9. The studies that used extracts and derived products of microorganisms are excluded from this table. As one can see, oncolytic viruses are mostly used for cancer therapy, especially in solid tumors, including ovarian cancer, bladder cancer, brain cancer, lung cancer, and gastrointestinal cancers. Moreover, to some extent, the anti-tumor effects of oncolytic viruses are somehow limited, and thus, they are employed with chemotherapeutic drugs together. Bacteria are mostly applied in cancer diagnosis or detecting the relationship between bacteria and cancers. Fang group screened the gut microbiota of colorectal cancer patients and found that the *Fusobacterium Nucleatum* and *Clostridium symbiosum* could be used to diagnose colorectal cancer (Figure 15, Table 9, Clinical Trial No. NCT02845973) [187]. Fecal microbiota is also positively correlated with breast cancer and thus could be employed for early diagnosis of breast cancer (Table 9, Clinical Trial No. NCT01461070). Topical bacteriophage T4 endonuclease V shows positive effects in preventing the recurrence of skin cancer in patients undergoing kidney transplants (Table 9, Clinical Trial No. NCT00089180). Intravenous injection of oncolytic virus HSV-1 (HSV1716) is
applied to chemotherapy for the treatment of different solid tumors, including cholangiocarcinoma, pancreatic neuroendocrine tumor, Ewing sarcoma, osteosarcoma, etc (Figure 16, Table 9, Clinical Trial No. NCT00931931) [188]. Engineered Listeria are used for immunotherapy to treat prostate cancer (Table 9, Clinical Trial No. NCT02625857). Protobics and low-bacteria diet act as adjuvants for potentially treating cancers. There are no completed clinical trials

in these databases showing the application of fungi and protozoa in cancer theranostics. However, some products related to them are generated in this area. For instance, Imprime PGG, isolated from the cell wall of Saccharomyces cerevisiae, together with pembrolizumab, is being tested for its therapeutic effects on triple-negative breast cancer and melanoma (Clinical Trial No. NCT02981303).

Table 9. Clinical Trials of microorganisms applied for cancer theranostics

| Microorganisms | Tumor type | Clinical Studies | Year | Database (ID) |
|----------------|------------|-----------------|------|---------------|
| T4 phage       | Skin Cancer | T4N5 Liposomal Lotion in Preventing the Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant | 2004-2007 | ClinicalTrials.gov [a] (NCT00689180) |
| MV-CEA, and MV-NIS (Oncolytic virus) | Ovarian cancer | Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients with Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer | 2004-2017 | ClinicalTrials.gov (NCT00408590) |
| GL-ONC1 (Oncolytic virus) | Solid Tumors | Safety Study of GL-ONC1, an Oncolytic Virus, in Patients with Advanced Solid Tumors | 2008-2015 | ClinicalTrials.gov (NCT00794131) |
| CG0070 (Oncolytic virus) | Bladder Cancer | Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure | 2015-2019 | ClinicalTrials.gov (NCT02363818) |
| TBI-1401 (HF10) (Oncolytic virus) | Solid Tumor | A Study of TBI-1401(HF10) in Patients with Solid Tumors with Superficial Lesions | 2015-2017 | ClinicalTrials.gov (NCT02429036) |
| Enadenotucirev (Oncolytic virus) | Ovarian Cancer | Phase I / Dose Expansion Study of Enadenotucirev in Ovarian Cancer Patients | 2014-2019 | ClinicalTrials.gov (NCT02028117) |
| Enadenotucirev (Oncolytic virus) | Solid Tumours | Phase I / II Study of Enadenotucirev by sub-acute Fractionated IV Dosing in Cancer Patients | 2012-2016 | ClinicalTrials.gov (NCT02028442) |
| G207 (Oncolytic virus) | Brain Cancer | Safety and Effectiveness Study of G207, a Tumor-Killing Virus, in Patients with Recurrent Brain Cancer | 2001-2003 | ClinicalTrials.gov (NCT00028158) |
| Colo-Ad1 (Oncolytic virus) | Colon Cancer; Non-small Cell Lung Cancer; Bladder Cancer; Renal Cell Carcinoma | Mechanism of Action Trial of ColoAd1 | 2013-2016 | ClinicalTrials.gov (NCT02053220) |
| ONCOS-102 (Oncolytic virus) | Solid Tumour | ONCOS-102 (Previously CGTG-102) for Therapy of Advanced Cancers | 2012-2013 | ClinicalTrials.gov (NCT01598129) |
| HSV1716 (Oncolytic virus) | Solid Tumour | HSV1716 in Patients with Non-Central Nervous System (Non-CNS) Solid Tumors | 2010-2018 | ClinicalTrials.gov (NCT00319361) |
| DNX-2401 (Oncolytic virus) | Brain Tumors | DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors | 2014-2018 | ClinicalTrials.gov (NCT02197169) |
| VCN-01 (Oncolytic virus) | Solid Tumors | Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients with Advanced Solid Tumors | 2014-2020 | ClinicalTrials.gov (NCT02045602) |
| Ad-MAGEA3, MGI-MAGEA3 (Oncolytic virus) | Non-Small Cell Lung Cancer | Oncolytic MGI-MAGEA3 With Ad-MAGEA3 Vaccine in Combination with Pembrolizumab for Non-Small Cell Lung Cancer Patients | 2017-2020 | ClinicalTrials.gov (NCT02879760) |
| HSV1716 (Oncolytic virus) | Mesothelioma | Intrapleural Administration of HSV1716 to Treat Patients with Malignant Pleural Mesothelioma | 2012-2016 | ClinicalTrials.gov (NCT01721018) |
| REOLYSIN® (Oncolytic virus) | Colorectal Cancer | Study of REOLYSIN® in Combination with FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer | 2010-2018 | ClinicalTrials.gov (NCT01274624) |
| GL-ONC1 (Oncolytic virus) | Cancer of Head and Neck | Safety Study of Attenuated Vaccinia Virus (GL-ONC1) with Combination Therapy in Head & Neck Cancer | 2012-2015 | ClinicalTrials.gov (NCT01582484) |
| JX-594 (Oncolytic virus) | Hepatic Carcinoma | A Study of Recombinant Vaccinia Virus to Evaluate the Safety and Efficacy of a Transdermal Injection Within the Tumor of Patients with Primary or Metastatic Hepatic Carcinoma | 2006-2007 | ClinicalTrials.gov (NCT00629759) |
| JX-594 (Oncolytic virus) | Liver Cancer | A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib | 2008-2011 | ClinicalTrials.gov (NCT01387555) |
| DNX-2401 (Oncolytic virus) | Brain Cancer | Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects | 2016-2021 | ClinicalTrials.gov (NCT02798406) |
| REOLYSIN® (Oncolytic virus) | Non-small Cell Lung Carcinoma | Phase 2 Study of REOLYSIN® in Combination with Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation | 2009-2015 | ClinicalTrials.gov (NCT00861627) |
| CVA21 (Oncolytic virus) | Uveal Melanoma; Liver Metastases | CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER) | 2018-2019 | ClinicalTrials.gov (NCT03408887) |
| JX-594 (Oncolytic virus) | Solid Tumors | Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors | 2008-2014 | ClinicalTrials.gov (NCT00625456) |
| VCN-01 (Oncolytic virus) | Pancreatic Adenocarcinoma | A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections with Gemcitabine and Abraxane® in Patients with Advanced Pancreatic Cancer | 2014-2018 | ClinicalTrials.gov (NCT02045899) |
| JX-594 (Oncolytic virus) | Solid Tumors | Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients | 2010-2014 | ClinicalTrials.gov (NCT01169984) |
| REOLYSIN® (Oncolytic virus) | Malignant Glioma | Safety and Efficacy Study of REOLYSIN® in the Treatment of Recurrent Malignant Gliomas | 2006-2010 | ClinicalTrials.gov (NCT00526884) |
| GL-ONC1 (Oncolytic virus) | Peritoneal Carcinomatosis | A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients with Advanced Peritoneal Carcinomatosis | 2012-2014 | ClinicalTrials.gov (NCT01442360) |
| TBI-1401 (HF10) (Oncolytic virus) | Melanoma | A Study of Combination With TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic Melanoma | 2017-2018 | ClinicalTrials.gov (NCT01530853) |
| HF10 (Oncolytic virus) | Melanoma | A Study of Combination Treatment with HF10 and Ipilimumab in Patients With | 2014-2018 | ClinicalTrials.gov |
| Microorganisms                  | Tumor type                                    | Clinical Studies                                                                                                                                                                                                 | Year       | Database (ID) |
|--------------------------------|-----------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|
| JX-944 (Oncolytic virus)       | Colorectal Carcinoma                          | Unresectable or Metastatic Melanoma                                                                                                                                                                                  | 2012-2015  | ClinicalTrials.gov (NCT02272855) |
| REOLYSIN® (Oncolytic virus)    | Sarcomas                                       | Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung                                                                                                                                                      | 2007-2011  | ClinicalTrials.gov (NCT01394039) |
| CV2A1 (Oncolytic virus)        | Melanoma                                       | A Study of Intratumoral CAVATAR™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM)                                                                                                                                                    | 2011-2016  | ClinicalTrials.gov (NCT01227551) |
| JX-944 (Oncolytic virus)       | Melanoma                                       | A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma                                                                                                                                              | 2007-2009  | ClinicalTrials.gov (NCT00429512) |
| CVA21 (Oncolytic virus)        | Melanoma                                       | A Safety Study of Two Intratumoral Doses of Coxsackievirus Type A21 in Melanoma Patients (PSX-003)                                                                                                              | 2007-2009  | ClinicalTrials.gov (NCT01436009) |
| ParvOryx (Oncolytic virus)     | Glioblastoma                                   | Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme.                                                                                                         | 2011-2015  | ClinicalTrials.gov (NCT01301430) |
| REOLYSIN® (Oncolytic virus)    | Pancreatic Adenocarcinoma                     | Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma                                                                                                   | 2015-2018  | ClinicalTrials.gov (NCT02620423) |
| DNX2401 (Oncolytic virus)      | Glioblastoma                                   | Virus DNX2401 and Temozolomide in Recurrent Glioblastoma                                                                                                                                                     | 2013-2017  | ClinicalTrials.gov (NCT0195674) |
| REOLYSIN® (Oncolytic virus)    | Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | Paclitaxel With or Without Vizal Therapy in Treating Patients with Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer After Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PDI) Blockade | 2010-2020  | ClinicalTrials.gov (NCT01199263) |
| MV-NIS (Oncolytic virus)       | Myeloma                                        | UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonton Strain of Measles Virus                                                                                           | 2015-2019  | ClinicalTrials.gov (NCT02192775) |
| Pexa Vec (Oncolytic virus)     | Hepatocellular Carcinoma                      | Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone                                                                                           | 2015-2020  | ClinicalTrials.gov (NCT02562755) |
| JX-944 (Oncolytic virus)       | Hepatocellular Carcinoma                      | A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma                                                                                                                      | 2008-2013  | ClinicalTrials.gov (NCT01554372) |
| MV-NIS (Oncolytic virus)       | Mesothelioma                                   | Intrapleural Measles Virus Therapy in Patients with Malignant Pleural Mesothelioma                                                                                                                               | 2011-2019  | ClinicalTrials.gov (NCT01503177) |
| T-VEC (Oncolytic virus)        | Melanoma                                       | A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma                                                                                                                              | 2005-2008  | ClinicalTrials.gov (NCT00280816) |
| ONCOS-102                      | Melanoma                                       | A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients with Advanced or Unresectable Melanoma Processing After Programmed Cell Death Protein 1 (PDI) Blockade | 2016-2020  | ClinicalTrials.gov (NCT03003676) |
| ParvOryx (Oncolytic virus)     | Pancreatic Cancer                              | A non-controlled, single arm, open label, Phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer | 2015-2018  | EudraCT [b] (2015-001119-11) |
| ParvOryx (Oncolytic virus)     | Glioblastoma                                   | Phase I/II study of intratumoral/intracerebral or intravenous/intracerebral administration of ParvOryx H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme | 2011-2015  | EudraCT (2011-000572-33) |
| HSV1716 (Oncolytic virus)      | Pleural mesothelioma                           | A Phase I/II Study Of The Safety, Tolerability And Biological Effect Of Single And Repeat Administration Of The Selectively Replication-Competent Herpes Simplex Virus Hsv1716 Into The Tumour-Bearing Pleural Cavity (Intrapleural) In Patients With Inoperable Malignant Pleural Mesothelioma | 2012-2016  | EudraCT (2010-024496-37) |
| Pexa-Vect (Oncolytic virus)    | Hepatocellular carcinoma                      | A Phase I/IIa trial to evaluate the safety and efficacy of the combination of the oncolytic immunotherapy Pexa-Vect with the PD-1 receptor blocking antibody nivolumab in the first-line treatment of advanced hepatocellular carcinoma (HCC) | 2018-2020  | EudraCT (2016-000853-32) |
| ONCOS-102 (Oncolytic virus)    | Pleural mesothelioma                           | A randomised Phase II open label study with a Phase IIb safety lead-in cohort of ONCOS-102, an immune-priming GM-CSF coding oncolytic adenovirus, and pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma | 2019-2018  | EudraCT (2015-00514-13) |
| T-VEC (Oncolytic virus)        | Melanoma                                       | A Phase Ib/2, Multicenter, Open-label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec and Ipilimumab Compared to Ipilimumab Alone in Subjects With Unresected, Stage III-BIV Multiforme | 2014-2021  | EudraCT (2012-000307-32) |
| VNP20099 (Bacteria)            | Cancer                                         | Treatment of Patients With Cancer With Genetically Modified Salmonella Typhimurium Bacteria                                                                                                                          | 2000-2002  | ClinicalTrials.gov (NCT00004988) |
| Lactobacillus plantarum HEAL 19 (Bacteria) | Rectal Cancer                                | Action of Synbiotics on Irradiated GI Mucosa in Rectal Cancer Treatment                                                                                                                                         | 2008-2015  | ClinicalTrials.gov (NCT03420443) |
| Intestine bacteria             | Breast Cancer                                  | Intestine Bacteria and Breast Cancer Risk                                                                                                                                                                | 2011-2020  | ClinicalTrials.gov (NCT01461070) |
| Gut bacteria                   | Breast Cancer                                  | Engineering Gut Microbiome to Target Breast Cancer                                                                                                                                                    | 2017-2020  | ClinicalTrials.gov (NCT0338511) |
| Gut bacteria                   | Colorectal cancer                              | Study of Fecal Bacteria in Early Diagnosis of Colorectal Cancer                                                                                                                                              | 2012-2017  | ClinicalTrials.gov (NCT02845973) |
| Bacteria vaccine               | Cancer                                         | A Phase I Study of Mixed Bacteria Vaccine (MBV) in Patients with Tumors Expressing NY-ESO-1 Antigen                                                                                                               | 2007-2013  | ClinicalTrials.gov (NCT00623831) |
| C. novyi-NT (Bacteria)         | Solid Tumor                                    | Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores To Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies                                                                 | 2013-2017  | ClinicalTrials.gov (NCT0126589) |
| Colistimethate sodium (Bacteria) | Haematological Malignancies (DEHAM)          | A Study of DÉColonization in Patients with HAEmatological Malignancies (DEHAM)                                                                                                                                   | 2017-2017  | ClinicalTrials.gov (NCT02964547) |
| Bacteria                      | Malignant Neoplasm                             | Peritoneal Bacterial Contamination Following Resection With Closed or Open Rectal Stump for Left-sided Cancer                                                                                           | 2014-2014  | ClinicalTrials.gov (NCT02527882) |
| Bacteria                      | Breast Cancer                                  | Effects of Chemotherapy on Intestinal Bacteria in Patients With Newly Diagnosed Breast Cancer                                                                                                                         | 2014-2018  | ClinicalTrials.gov (NCT03207027) |
| AG013 (Bacteria)               | Head and Neck Cancer                           | Study to Assess Safety and Tolerability of AG013 in Oral Mucositis in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck                                                   | 2009-2012  | ClinicalTrials.gov (NCT00938860) |
| Oral bacteria                  | Pancreatic Cancer                              | Oral Microbiome and Pancreatic Cancer                                                                                                                                                                | 1992-2010  | ClinicalTrials.gov |

https://www.thno.org
| Microorganisms | Tumor type | Clinical Studies | Year | Database (ID) |
|----------------|------------|-----------------|------|---------------|
| La1, BB536 (Bacteria) | Colorectal Cancer | Probiotics In Colorectal Cancer Patients | 2006-2007 | ClinicalTrials.gov (NCT00936572) |
| Bi-04, NCFM (Bacteria) | Colon cancer | Using Probiotics to Reactivate Tumor Suppressor Genes in Colon Cancer | 2010-2016 | ClinicalTrials.gov (NCT03072641) |
| JNJ-64041809 (Bacteria) | Prostate Cancer | Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer | 2015-2018 | ClinicalTrials.gov (NCT02625857) |
| Bacteria | Leukemia; Sarcoma; Neuroblastoma | The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients | 2007-2017 | ClinicalTrials.gov (NCT00726934) |
| Bacteria | Skin Cancer | Observational Study to Investigate Surgical Site Infection in Ulcerated Skin Cancers | 2019-2020 | ClinicalTrials.gov (NCT03782277) |
| Bacteria | Gastric Cancer | Gastric Cancer Precursor Lesions (GCPL) Study | 2017-2020 | ClinicalTrials.gov (NCT0188406) |
| Intestinal microbiome | Gastric Cancer | Intestinal Microbiome After Gastrectomy | 2018-2019 | ClinicalTrials.gov (NCT03418428) |
| Bacteria | Colorectal cancer, Stomach cancer, Pancreatic Cancer | Tracheal Colonization and Outcome After Major Abdominal Cancer Surgery | 2008-2012 | ClinicalTrials.gov (NCT040202128) |
| Bacteria | Colorectal cancer | Symbiotics and Gastrointestinal Function Related Quality of Life After Colectomy for Cancer | 2010-2015 | ClinicalTrials.gov (NCT01479907) |
| Bacteria | Colorectal Cancer | Microbiota-anastomotic Leak Among Colorectal Surgery Patients: Pilot Study | 2018-2018 | ClinicalTrials.gov (NCT0349441) |
| Fluoroquinolone Resistant Enteric Bacteria | Prostate cancer | Incidence of Fluoroquinolone Resistant Bacteria in Patients Undergoing Prostate Biopsy | 2015-2016 | ClinicalTrials.gov (NCT02104502) |
| Fecal Microbiota | Leukemia | Prevention of Dysbiosis Complications With Autologous FMT in AML Patients | 2016-2018 | ClinicalTrials.gov (NCT02989523) |
| Gut microbiome | Colorectal Adenoma | Ginger and Gut Microbiome | 2018-2020 | ClinicalTrials.gov (NCT0368665) |
| Probiotics (Bacteria) | Hepatocellular Carcinoma | Influence of Probiotics Administration Before Liver Resection in Liver Disease | 2013-2018 | ClinicalTrials.gov (NCT02021253) |
| BCG (Bacteria) | Bladder cancer | A Phase III Randomized, Open-Label, Multi-Center, Global Study of Durvalumab and Bacillus Calmette-Guerin (BCG) Administered as Combination Therapy Versus BCG Alone in High-Risk, BCG Native Non Muscle Invasive Bladder Cancer Patients | 2017-2019 | EudraCT (2017-002979-26) |

*Results from ClinicalTrials.gov (https://clinicaltrials.gov/); b) Results from EudraCT (https://www.clinicaltrialregister.eu)*

**Figure 16.** Decreased tumor metabolic activity shown in a patient after HSV1716 administration. Adapted with permission from [188]. Copyright 2019, Elsevier Ltd, CC BY-NC-ND 4.0.
7. Challenges and future perspectives

Traditional detection for microbiota is normally based on culturing specific microorganisms. According to the theory of microorganism detection, we should get a general knowledge of what the microorganisms need for survival; they can be cultured for us to observe their characteristic growth features. For instance, as for bacteria, we can only know their category on the premise of knowing their colony-forming units, such as filamentous colony, undulate colony, spore colony and etc. Therefore, we cannot identify the microorganisms if we do not have any records of their characteristics unless we do not have the technologies to culture them in vitro. To fill this gap, biologists invented a new measurement to identify the microorganisms on the basis of different metabolites of different microorganisms. This technology, called metabolome, can detect the profile of the metabolites in cells [189]. Yet, it is still challenging for biologists to deeply get insights into microorganism verification. The most straitened circumstance is that microorganisms excrete similar (or even the same) metabolites so that we cannot distinguish them. Therefore, to further verify these microorganisms, a more specific and precise method is needed.

In recent years, the measurement of microbiota based on 16S sequencing has been adopted for microbiologists to explore the spectra of microorganisms and further classify them. However, 16S sequencing is contrived in light of the high conservative structure and function of the 16S rDNA in bacteria. The main drawbacks of 16S sequencing for detecting microbiota lie in the errors and low sensitivity in detecting heterogeneity of intra-species [190]. Also, it is not appropriate for other microorganisms such as viruses and fungi. To better solve these problems, whole-metagenome sequencing was launched to map the genomic regions precisely. Whole-metagenome sequencing gives new insights to deeply observe the genome in the microbiota as a result of the development of next-generation sequencing technologies. Global archives have been established and have stored millions of datasets for bacterial and viral whole-metagenome sequencing [191]. There is no doubt that more categories will be identified and classified based on whole-metagenome sequencing in the future.

As massive microbiota spectra have been established, there comes the development of TME research and cancer therapy. On the one hand, we can obtain certain parts of tumor tissues and submit them to whole-metagenome sequencing to find out whether there is microbiota living in them or not. If so, we can substantially excogitate their roles in TME and cancer development, for example, to understand whether they help contribute to tumor proliferation, metastasis or inhibit them through secreting specific small molecules or cooperating with immune cells. On the other hand, we can compare the similarities and differences of different cancer TME and further establish datasets for TME microbiota. Doing so will help better understand the TME and build a foundation for cancer immunotherapy.

Even though many clinical trials have been down in the application of microorganisms for cancer theranostics, there are still some limitations and challenges. As we can see in Table 9, most completed trials directly using microorganisms in this field are using oncolytic viruses and bacteria. More explorations of phage, fungi, and protozoa in the clinical application should be investigated. Efforts should be made to evaluate not only the extracts and products of them but also the microorganisms themselves. Moreover, clinical tumor imaging and probe systems based on microorganisms are also limited and need further exploration. The most challenging part is the safety problems. Whether the microorganisms will only influence the tumor or not is important. If there will be side effects, how to decrease these effects after tumor treatment should be examined. Thus, more animal studies are welcome to discover the safety of microorganisms in individual bodies, in particular, to understand the immune response, the interaction between the introduced microorganisms and healthy tissues.

8. Conclusion

The applications of microorganisms for cancer theranostics have excited the oncologists in understanding the pathogenicity, diagnosis, progression, and treatment of cancer. Naturally, microorganisms reside in tumors, some of which are oncogenic, anti-tumoral, or just commensally residents. Many completed clinical trials have shown the diagnostic effects of microorganisms on the tumor. In addition, the anti-tumor functions of oncolytic viruses and bacteria have been widely launched clinically. However, more investigations should be done to evaluate the clinical values of phage, fungi, and protozoa. Due to the development of whole-metagenome sequencing, screening and identifying the specific microorganisms in certain tumor tissue has never been made easy like today. In this way, we can investigate the microbiota spectra of the tumor tissues and further distinguish their effects on cancer theranostics. Therefore, by uncovering the different impacts of the different microorganisms, we could deeply generate a precise probe, monitor,
vaccine, or drug for cancer diagnosis and therapy.

Abbreviations

BI2: B cell lymphoma/leukemia 2; CLRs: C-type lectin receptors; EBV: Epstein-Barr virus; EBNA-1: EBV-determined nuclear anti gen 1; EBNA-2: EBV-determined nuclear anti gen 2; FDS: fluorodeoxyxosorbitol; GFP: green fluorescent protein; HIF1α: hypoxia inducible factor-1 alpha; HIV: human immunodeficiency virus; IAP: inhibitor of apoptosis protein; IONP: iron oxide nanoparticles; JAK: Janus kinases; LMP-1: latent membrane protein1; LMP-2: latent membrane protein 2; MAPK: mitogen-activated protein kinase; MDM2: murine double minute 2; NIS: sodium/iodide symporter; NK: natural killer; NLRs: nucleotide oligomerization domain (NOD)-like receptors; QD: quantum dots; RLRs: retinoic acid-inducible gene 1 (RIG-I)-like receptors; T. annulata -1 alpha; TERT: telomerase reverse transcriptase; TGF-β: transforming growth factor-beta; TLRs: Toll-like receptors; TME: tumor microenvironment; TNF-α: tumor necrosis factor-alpha.

Acknowledgments

MY acknowledges the support of National Science Foundation (51673168, 81871499, 81871482, and 31800807). CM would like to thank the support from the Institute of Biomedical Engineering, Science and Technology of the University of Oklahoma.

Competing Interests

The authors have declared that no competing interest exists.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018. CA Cancer J Clin. 2018; 68: 394-424.
2. Najati M, Goradel NH, Farhoud B, Salehi E, Soltanpoor S, Toolee H, et al. Tumor microenvironment: Interactions and therapy. J Cell Physiol. 2019; 234: 5700-21.
3. Jobin C. Precision medicine using microbiota. Science. 2018; 359: 32-4.
4. El-Jurdi N, Ghannoum MA. The mycobiome: Impact on health and disease. Microbiol Spectr. 2017; 5: FUNK-0045-2016.
5. Dzutsev A, Goldszmid RS, Viaud S, Zitvogel L, Trinchieri G. The role of the microbiota in inflammation, carcinogenesis, and cancer therapy. Eur J Immunol. 2015; 45: 17-31.
6. Breban M. Gut microbiota and inflammatory joint diseases. Joint Bone Spine. 2016; 83: 645-9.
7. Serrano-Villar S, Rojo D, Martinez-Martinez M, Deusch S, Vazquez-Castellanos JF, Sainz T, et al. HIV infection results in metabolic alterations in the gut microbiota different from those induced by other diseases. Sci Rep. 2016; 6: 26192.
8. Hsiao EY, McBride SW, Hsien S, Sharon G, Hyde ER, McCue T, et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell. 2013; 153: 1451-63.
9. Qin N, Yang F, Li A, Pritfi E, Chen Y, Shao L, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature. 2014; 513: 59-64.
10. Arthur JC, Jobin C. The struggle within: microbial influences on colorectal cancer. Inflamm Bowel Dis. 2011; 17: 396-409.
11. van der Velden WJ, Netea MG, de Haan AF, Huls GA, Donnelly JP, Blijlevens NM. Role of the mycobiome in human acute graft-versus-host disease. Biol Blood Marrow Transplant. 2013; 19: 392-39.
12. Qin J, Li Y, Cai Z, Li Z, Zhu J, Zhang F, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012; 490: 55-60.
13. Dzutzew A, Badger JH, Perez-Chanona E, Roy S, Saleedo R, Smith CK, et al. Microbes and cancer. Annu Rev Immunol. 2017; 35: 199-228.
14. Kalschotstrom CT, Pariente NM, Weiss U. Intestinal microbiota in health and disease. Nature. 2016; 535: 47.
15. Naik S, Bouladoux N, Linehan JL, Han SJ, Harrison OJ, Wilhelm C, et al. Commensal-dendritic-cell interaction specifies a unique protective skin immune signature. Nature. 2015; 520: 104-8.
16. O’Brien S, Fothergill JL. The role of multispecies social interactions in shaping Pseudomonas aeruginosa pathogenicity in the cystic fibrosis lung. FEMS Microbiol Lett. 2017; 364: fmx128.
17. Hawesler NB, Nethushil L. The oral microbiota. Adv Exp Med Biol. 2016; 902: 45-60.
18. Di Pilato V, Freschi G, Ringressi MN, Pallecchi L, Rossolini GM, Bephi P. The esophageal microbiota in health and disease. Ann N Y Acad Sci. 2016; 1381: 163.
19. Alarcon T, Llorca L, Perez-Perez G. Impact of the microbiota and gastric disease development by Helicobacter pylori. Curr Top Microbiol Immunol. 2017; 400: 253-75.
20. Chase CCL. Enteric immunity: Happy gut, healthy animal. Vet Clin North Am Small Anim Pract. 2018; 34: 1-18.
21. Neuman H, Koren O. The Pregnancy Microbiome. Nestle Nutr Inst Workshop Ser. 2017; 88: 1-9.
22. Asar M, Newton-Northup J, Deutscher S, Soendergaard M. Ovarian cancer targeting phage for ir vivo near-infrared optical imaging. Diagnostics (Basel). 2019; 9: 183.
23. Ebrahimi S, Teimoori A, Khanbabaei H, Tabasi M. Harnessing CRISPR/Cas9 System for manipulation of DNA virus genome. Rev Med Virol. 2018: e2009.
24. Cao B, Li Y, Yang T, Bao Q, Yang M, Mao C. Bacteriophage-based biomaterials for tissue regeneration. Adv Drug Deliv Rev. 2019; 145: 73-95.
25. Yue GG, Chan BC, Han XQ, Cheng L, Wong EC, Leung PC, et al. Immunomodulatory activities of Gadenornia sinense polysaccharides in human immune cells. Nutr Cancer. 2013; 65: 765-74.
26. Evangelopoulos M, Parodi A, Martinez JO, Tasciotti E. Trends towards biomimicry in theranostics. Nanomaterials (Basel). 2018; 8: 637.
27. Blanche C, Bauwens E, Tay A, Peters F, Dobbs S, Dobbs J, et al. A novel isolation protocol and probe-based RT-PCR for diagnosis of gastric infections with the zoonotic pathogen Helicobacter suis. Helicobacter. 2017; 22: e1269.
28. Gong X, Li Z, Hu Q, Zhou R, Shuang S, Dong C. N,S,P co-doped carbon nanodot fabricated from waste microorganism and its application for label-free recognition of manganese(VII) and L-ascorbic acid and an logic gate in a living body. Biomaterials. 2017; 141: 136-48.
29. Jiang P, Wang L, Hou B, Zhou J, Zhu M, Jiang J, et al. A novel HPV16 E7-affitoxin for targeted therapy of HPV16-induced human cervical cancer. Theranostics. 2018; 8: 3544-58.
30. Bateam A, Eddy SR, Muyazhunizhov VV. A member of the immunoglobulin superfAMILY in bacteriophage T4. Virus Genes. 1997; 14: 163-5.
31. Gamrekzelidze M, Dabrowska K. T4 bacteriophage as a phage display platform. Arch Microbiol. 2014; 196: 473-9.
32. Wongsrichana P, Diaz RM, Galivo F, Kottke T, Thompson J, Melcher A, et al. V59 oncolytic virotether in the B16 model depends upon intact MyD88 signaling. Mol Ther. 2011; 19: 150-8.
33. Chavez-Arroyo D, Portnoy DA. Why is Listeria monocytogenes such a potent inducer of CD8+ T-cells? Cell Microbiol. 2020; 22: e13175.
34. Han W, Chen H, Zhou L, Zou H, Luo X, Sun B, et al. Polysaccharides from Ganoderma Sinense - rice bran fermentation products and their anti-tumor activities on non-small-cell lung cancer. BMC Complement Med Ther. 2021; 21: 169.
35. Ubillos L, Freire T, Berriel E, Chiribao ML, Chiale C, Festari MF, et al. Trypanosoma cruzi extracts elicit protective immune response against chemically induced colon and mammary cancers. Int J Cancer. 2016; 138: 1719-31.
36. Walker K. Use of bacteriophages as novel food additives. FSfOAN. 2006; 490: 811.
37. Kutter E, SulavkCELide A. Bacteriophages: Biology and applications. 1st Edition. ed. Boca Raton: CRC Press. 2004.
38. Ivanovskaya IL, de Pablo PJ, Bjarra B, Sgalari G, MacKintosh FC, Carrascosa JL, et al. Bacteriophage capsids: tough nanoshells with complex elastic properties. Proc Natl Acad Sci U S A. 2004; 101: 7600-5.
39. Akkervdyan VZ, Gaz RK, Tokmakova IL, Stoyanova NV, Yomantas YA, Markov SV. Application of the bacteriophage Mu-driven system for the integration/amplification of target genes in the chromosomes of engineered Gram-negative bacteria--mini review. Appl Microbiol Biotechnol. 2011; 91: 171-87.
40. Simpson AA, Tao Y, Leiman PG, Badasso MO, He Y, Jardine PJ, et al. Structure of the bacteriophage phi29 DNA packaging motor. Nature. 2000; 408: 745-50.
adenvirus: The role of adenvirus death protein deletion. Mol Ther Oncolytics. 2021; 20: 659-68.

160. Veerapong J, Bickenbach KA, Shao MY, Smith KD, Posner MC, Rozman B, et al. Systematic delivery of (gamma)34.5-deleted herpes simplex virus-1 selectively targets and treats distant human xenograft tumors that express high MEK activity. Cancer Res. 2007; 67: 8301-6.

161. Maesoul P, Iankov ID, Allen C, Morris JC, von Messling V, Cattaneo R, et al. Cell-mediated measles virus as a novel oncolytic therapy against prostate cancer. Prostate. 2009: 69-92: 82.

162. Xu P, Wang X, Li Y, Qiu J. Establishment of a Parvovirus B99 NS1-expressing recombinant adenovector for killing megakaryocyte leukemia cells. Viruses. 2019; 11: 820.

163. Haddad D, Chen NG, Zhang Q, Chen YU, Yu KA, Gonzalez L, et al. Insertion of the human sodium iodide symporter to facilitate deep tissue imaging does not alter oncolytic or replication capability of a novel vaccinia virus. J Transl Med. 2011; 9: 36.

164. Mounavi M, Fazli Z, Learle H, Gao Y, Cox M, Bell J, et al. Oncolyis of prostate cancers induced by vesicular stomatitis virus in PTEN knockout mice. Cancer Res. 2010; 70: 1367-76.

165. El-Sayed A, Bernhard W, Barreto K, Gonzalez C, Hill W, Pastushok L, et al. A phase I safety and pharmacokinetic study of the death receptor 5 transgene expression after fusion to early or late viral genes of a conditionally replicating vaccinia virus. Virology. 2004; 320: 121-34.

166. Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW. Fusobacterium theranostics. Cytokine Growth Factor Rev. 2010; 21: 91-8.

167. Aykut B, Pushalkar S, Chen R, Li Q, Abengozar R, Kim JI, et al. The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL. Nature. 2014; 510: 128-39.

168. Atasheva S, Emerson CC, Yao J, Young C, Stewart PL, Shakhaymovt DM. Systemic cancer therapy with engineered adenovirus that evades innate immune recognition. J Transl Med. 2012: e240-69.

169. Gromeier M, Nair SK. Recombinant Poliovirus for Cancer Immunotherapy. Annu Rev Med. 2018; 69: 289-99.

170. Msaouel P, Iankov ID, Allen C, Morris JC, von Messling V, Cattaneo R, et al. A phase Ib/2 trial of mapatumumab in patients with relapsed/ refractory colorectal cancer through suppressing hedgehog signaling. Exp Biol Med (Maywood). 2018; 6: 48.

171. Liao Y, Ling J, Zhang G, Liu F, Tao S, Han Z, et al. Cordycepin induces cell death in prostate cancer cells via the sodium iodide symporter gene. Blood. 2007; 110: 2342-50.

172. Wong JH, Sze SCW, Ng TB, Cheung RCF, Tam C, Zhang KY, et al. Apoptosis activity and cytotoxicity. Protein Pept Lett. 2004; 11: 563-9.

173. Ma L, Chen H, Dong P, Lu X. Anti-inflammatory and anticancer activities of the polypeptide from Pleurotus eryngii mycelium. Int J Biol Macromol. 2003; 28: 2858.
164. Linh DT, Hien BT, Que do D, Lam DM, Arnold N, Schmidt J, et al. Cytotoxic constituents from the Vietnamese fungus Xylaria schweinitzii. Nat Prod Commun. 2014; 9: 659-68.

165. Li M, Zhang G, Ng TB, Wang H. A novel lectin with antiproliferative and HIV-1 reverse transcriptase inhibitory activities from dried fruiting bodies of the monkey head mushroom Hericium erinaceum. J Biomed Biotechnol. 2010; 2010: 716515.

166. Zhao S, Zhao Y, Li S, Zhao J, Zhang G, Wang H, et al. A novel lectin with highly potent antiproliferative and HIV-1 reverse transcriptase inhibitory activities from the edible wild mushroom Russula delica. Glycoconjug J. 2010; 27: 259-65.

167. Zhang G, Sun J, Wang H, Ng TB. First isolation and characterization of a novel lectin with potent antitumor activity from a Russula mushroom. Mycopharmacol. 2010; 17: 775-81.

168. Li M, Zhang G, Wang H, Ng T. Purification and characterization of a laccase from the edible wild mushroom Tricholoma mongolicum. J Microbiol Biotechnol. 2010; 20: 1069-76.

169. Vaz JA, Heleno SA, Martins A, Almeida GM, Vasconcelos MH, Ferreira IC. Wild mushrooms Clitocybe alexandri and Lepista inversa: in vitro antioxidant activity and growth inhibition of human tumour cell lines. Food Chem Toxicol. 2010; 48: 2881-4.

170. Arora D, Kumar A, Gupta P, Chashoo G, Jaglan S. Preparation, characterization and cytotoxic evaluation of bovine serum albumin nanoparticles encapsulating 5-methylmellitin: A secondary metabolite isolated from Xylaria psidii. Biorg Med Chem Lett. 2017; 27: 5126-30.

171. Noppawan S, Mongkolthanaruk W, Suwannasai N, Senawong T, Moontragoon P, Boonmak J, et al. Chemical constituents and cytotoxic activity from the wood-decaying fungus Xylaria sp. SFU08-37. Nat Prod Res. 2020; 34: 464-73.

172. Zhang L, Khoo C, Koyyalamudi SR, Pedro Nd, Reddy N. Antioxidant, anti-inflammatory and anticancer activities of ethanol soluble organics from water extracts of selected medicinal herbs and their relation with flavonoid and phenolic contents. Pharmacologia. 2017; p: 59-72.

173. Lin YS, Lin YY, Yang YH, Lin CL, Kuan FC, Lu CN, et al. Antrodia cinnamomea extract inhibits the proliferation of tamoxifen-resistant breast cancer cells through apoptosis and skp2/microRNAs pathway. BMC Complement Altern Med. 2018; 18: 152.

174. Zhang P, Li K, Yang G, Xia C, Polston JE, Li G, et al. Cytotoxic protein from the mushroom Coprinus comatus possesses a unique mode for glycan binding and specificity. Proc Natl Acad Sci U S A. 2017; 114: 6980-5.

175. Gu YH, Leonard J. In vitro effects on proliferation, apoptosis and colony inhibition in ER-dependent and ER-independent human breast cancer cells by extracts and compounds with suppressive action on breast cancer: evidence from studies using cultured cancer cells, tumor-bearing animals, and clinical trials. Appl Microbiol Biotechnol. 2020; 104: 4675-703.

176. Wang D, Sun SQ, Wu WZ, Yang SL, Tan JM. Characterization of a water-soluble polysaccharide from Boletus edulis and its antitumor and immunomodulatory activities on renal cancer in mice. Carbohydr Polym. 2014; 105: 127-34.

177. Torello CO, Souza-Queiroz J, Queiroz ML, beta-1,3-Glucan given orally in a symbiosum for noninvasive detection of early and advanced colorectal cancer: In vivo and anti-tumor effects of fungal extracts. Molecules. 2014; 19: 2546-56.

178. Thirukkumaran CM, Shi ZQ, Luiker J, Kopciuk K, Gao H, Bahlis N, et al. Reovirus as a viable therapeutic option for the treatment of multiple myeloma. Clin Cancer Res. 2012; 18: 4962-72.

179. Qi J, Zhang H, Wang Z. Auricularia auriculajudae polysaccharide-cisplatin complexes conjugated with folic acid as new tumor targeting agents. Int J Biol Macromol. 2018; 120: 966-74.

180. Konagai A, Yoshimura K, Hazama S, Yamamoto N, Aoki K, Ueno T, et al. Correlation Between NKGD2L Expression and Antitumor Effect of Protein-bound Polysaccharide-K in Tumor-bearing Mouse Models. Anticancer Res. 2017; 37: 4003-101.

181. Krishnamoorthy D, Sankaran M. Modulatory effect of Pleurotus ostreatus on oxidant/antioxidant status in 7, 12-dimethylbenz (a) anthracene induced mammary carcinoma in experimental rats--A dose-response study. J Cancer Res Ther. 2016; 12: 386-94.

182. Motamedi M, Arab S, Moazzemi SM, Khamis Abadi M, Hadjati J. Improvement of a dendritic cell-based therapeutic cancer vaccine with components of Toxoplasma gondii. Clin Vaccine Immunol. 2009; 16: 1393-8.